SBIR Phase I: Intraoperative Detection and Ablation of Microscopic Residual Cancer in the Tumor Bed

SBIR 第一阶段：术中检测并消融瘤床中的微小残留癌

• 批准号: 1046761
• 负责人: David Lee
• 金额: $ 14.75万
• 依托单位: Lumicell Diagnostics, Inc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1046761&HistoricalAwards=false
• 关键词: SBIR; Phase; Intraoperative; Detection; Ablation

This Small Business Innovation Research Phase I project will develop an intraoperative laser ablative device to simultaneously detect and treat residual cancerous cells in the tumor bed after bulk removal of tumors. Currently, the surgeon sends the resected tumor tissue to pathology to determine whether the surgical margins are clear (clean) of cancer cells. If the margins are not clean, the patient must return for a second surgery. We have developed a fluorescent molecular imaging agent and a wide-field-of-view imaging device to detect residual cancer cells with single cell resolution. The surface is illuminated by a laser and the imaging agent causes the cancer cells to fluoresce at a very specific wavelength. In this NSF-sponsored program, we propose to incorporate ablative technology to this imaging system so that the detected residual cancerous cells can be simultaneously detected and eliminated in real-time during the surgery. Specifically, we will incorporate ablation to our laser imaging system, register the pixel location of cancer targets, destroy the targets with the laser, and provide a feedback confirmation.The broader impacts/commercial potential of this project are improvements in patient care and reduction of healthcare costs. Currently, around 50% of breast cancer patients and 35% of sarcoma patients require second tumor de-bulking surgeries because a final pathology report returns days after the initial surgery indicating that residual cancerous cells have been left within the patient. Furthermore, 25% of the final pathology reports do not detect residual cancer cells due to sampling errors fundamentally inherent in the process. Thus, most patients require subsequent medical therapy including additional radiation or chemotherapy treatment to prevent cancer recurrence and metastasis stemming from residual cancer cells. Our system will find and destroy residual cancer cells in real-time at a single cell level. Tumors adjacent to critical nerve or brain tissue are particularly difficult, and a laser therapy, guided by our imaging system, would allow the surgeon to thoroughly eradicate cancer cells with minimal added work and no adverse effect on surrounding tissue. Our novel single cell imaging device combined with focused laser ablative therapy will have a significant impact on preventing second surgeries and subsequent medical therapy, resulting in significant healthcare cost savings and improved patient care.

这个小企业创新研究第一阶段项目将开发一种术中激光消融装置，同时检测和治疗肿瘤大面积切除后肿瘤床上的残留癌细胞。目前，外科医生将切除的肿瘤组织送到病理学检查，以确定手术边缘是否清除（干净）癌细胞。如果边缘不干净，病人必须返回进行第二次手术。我们开发了一种荧光分子显像剂和一种宽视场成像装置，以单细胞分辨率检测残余癌细胞。表面由激光照射，显像剂使癌细胞在一个非常特定的波长发出荧光。在这个nsf赞助的项目中，我们建议将烧蚀技术结合到该成像系统中，以便在手术过程中同时检测和实时消除检测到的残留癌细胞。具体来说，我们将把消融纳入我们的激光成像系统，注册癌症目标的像素位置，用激光摧毁目标，并提供反馈确认。该项目的更广泛影响/商业潜力是改善患者护理和降低医疗保健成本。目前，大约50%的乳腺癌患者和35%的肉瘤患者需要进行第二次肿瘤切除手术，因为在初次手术后几天的最终病理报告表明患者体内残留了癌细胞。此外，25%的最终病理报告没有检测到残留的癌细胞，这是由于采样过程中根本固有的错误。因此，大多数患者需要后续的药物治疗，包括额外的放疗或化疗，以防止残留癌细胞引起的癌症复发和转移。我们的系统将在单个细胞水平上实时发现并摧毁残留的癌细胞。靠近关键神经或脑组织的肿瘤治疗尤其困难，在我们成像系统的指导下，激光治疗将允许外科医生以最少的额外工作彻底根除癌细胞，并且对周围组织没有不良影响。我们的新型单细胞成像设备与聚焦激光消融治疗相结合，将对防止第二次手术和随后的药物治疗产生重大影响，从而显著节省医疗成本并改善患者护理。